SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
856.00    23.00 (2.76%)
Bid:
855.00
Ask:
857.00
Spread: 2.00 (0.234%)
Market Cap: £808.15m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

13 Oct 2022 07:00

RNS Number : 7235C
Polar Capital Holdings PLC
13 October 2022
 

13 October 2022 Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides a quarterly update of its unaudited statement of Assets under Management ("AuM").

 

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 September 2022 its AuM were £18.8bn compared to £18.9bn at the end of the June quarter and £22.1bn at the end of March 2022. During the six-month period, AuM decreased by net redemptions of £0.8bn, outflows from previously reported fund closures of £0.5bn and a £2.0bn decrease related to market movement and fund performance.

 

AuM movement in six months to 30 September 2022

Open ended

funds

Investment

Trusts

Segregated mandates

Total

AuM at 1 April 2022

£16,590m

£4,378m

£1,153m

£22,121m

Net flows

£(753)m

£(62)m

£(30)m

£(845)m

Fund closures1

£(380)m

-

£(79)m

£(459)m

Market movement

and performance

£(1,374)m

£(611)m

£(66)m

£(2,051)m

Total AuM at

30 September 2022

£14,083m

£3,705m

£978m

£18,766m

1 Return of funds to investors on closure of the Phaeacian mutual funds and related segregated mandate in Q1.

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year. There is no certainty that the fees will be sustained over the next quarter, as performance fees can be volatile.

 

Performance fees

net of staff allocations

Six months to

30 Sept 21

Year to

31 Mar 22

(year-end)

Six months to

30 Sept 22

Received

-

£4.1m

-

Accrued but not yet earned in funds with year ends on or before the financial year end

£2m

n/a

£4.8m*

Total net performance fee profits

£2m

£4.1m

£4.8m*

\* The figures have been reduced by £1.0m of net performance fee distributions that relate to prior accounting periods that IFRS require to be deducted from this year's receipts.

 

 

Gavin Rochussen, Chief Executive, commented:

 

"There has been continued demand and inflows into the Global Insurance, Biotechnology, Healthcare Blue Chip, Smart Energy, European ex-UK Income, Emerging Market Stars, Forager and Global Absolute Return Funds, with combined net inflows of £260m across these funds in the quarter.

 

"A combination of the bear market sell-off, net outflows, fund closures and fund performance meant that our AuM at the end of the six-month period were £18.8bn compared to £18.9bn at the end of the previous quarter and £22.1bn at the end of March 2022. Total net outflows for the quarter were £529m.

 

"During the quarter, the rate of outflows from the open-ended Technology funds continued to decline, with £252m of outflows compared to £380m in the previous quarter and £630m in the first quarter of this calendar year. Outflows of £250m from the UK Value Opportunities Fund during the quarter reflected client asset allocation decisions with UK equity exposure being reduced.

 

"Despite the challenging back drop, we are pleased with the continuing progress in diversifying the business. The Smart funds managed by the Sustainable Thematic team have now collectively reached £150m. The Emerging Market Stars team have had success in the US with the Emerging Market Stars Mutual Fund raising its first £50m.

 

"The well-established Polar Capital Global Insurance fund has continued to deliver robust performance with net inflows of £257m in the six months. The team's low appetite for catastrophe risk has protected investor returns with the Fund well positioned to benefit from ongoing premium rate rises in commercial insurance and a recent acceleration in reinsurance pricing. For the calendar year to September 2022, the fund has achieved absolute positive performance of 12.2% which is 6.5% ahead of its benchmark.

 

"We remain confident that with our diverse range of differentiated, active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)Samir Ayub (Finance Director)

+44 (0)20 7227 2700

 

Numis Securities Limited - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

Stephen Westgate

 

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

 

 

+44 (0)20 3597 8680

 

Camarco

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4995

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAEEDFFFAFEA
Date   Source Headline
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:37 pmRNSPrice Monitoring Extension
19th Mar 202012:07 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
12th Mar 20208:37 amRNSIssue of Equity
2nd Mar 20207:00 amRNSTotal Voting Rights
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
21st Feb 202011:51 amRNSForm 8.3 - Redde PLC
21st Feb 20209:59 amRNSIssue of Equity
20th Feb 20201:54 pmRNSForm 8.3 - Redde PLC
18th Feb 202011:14 amRNSForm 8.3 - Redde PLC
18th Feb 202010:28 amRNSChange of Auditor
17th Feb 20202:44 pmRNSForm 8.3 - Redde PLC
13th Feb 20202:37 pmRNSIssue of Equity
13th Feb 20207:00 amRNSTeam Acquisition
7th Feb 20201:09 pmRNSForm 8.3 - Redde PLC
6th Feb 20202:45 pmRNSForm 8.3 - Redde PLC
5th Feb 20202:33 pmRNSForm 8.3 - Redde PLC
3rd Feb 202011:14 amRNSBlock listing Interim Review
28th Jan 20201:06 pmRNSForm 8.3 - Redde PLC
22nd Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
21st Jan 20202:26 pmRNSForm 8.3 - Redde PLC
21st Jan 20202:12 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20202:01 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20201:37 pmRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
16th Jan 202012:28 pmRNSForm 8.3 - Redde PLC
16th Jan 202012:26 pmRNSForm 8.3 - Consort Medical PLC
15th Jan 202012:20 pmRNSForm 8.3 - Redde PLC
14th Jan 202012:00 pmRNSForm 8.3 - Redde PLC
13th Jan 20201:49 pmRNSForm 8.3 - Redde Plc
10th Jan 20201:09 pmRNSForm 8.3 - Redde Plc
9th Jan 20207:00 amRNSAuM Update
30th Dec 201912:35 pmRNSForm 8.3 - Redde PLC
24th Dec 201911:35 amRNSForm 8.3 - Redde PLC
23rd Dec 20193:24 pmRNSForm 8.3 - Redde PLC
20th Dec 201911:18 amRNSForm 8.3 - Redde PLC
19th Dec 20192:17 pmRNSForm 8.3 - Redde PLC
18th Dec 20191:42 pmRNSForm 8.3 - Consort Medical PLC
17th Dec 201910:58 amRNSForm 8.3 - Consort Medical Plc
17th Dec 20199:37 amRNSHolding(s) in Company
6th Dec 20191:09 pmRNSForm 8.3 - Consort Medical Plc
5th Dec 20192:24 pmRNSForm 8.3 - Consort Medical Plc
4th Dec 20191:22 pmRNSForm 8.3 - Consort Medical Plc
2nd Dec 20191:59 pmRNSForm 8.3 - Redde PLC
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 20197:00 amRNSUnaudited interim results
20th Nov 20194:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.